Start-Up Quarterly Statistics, Q4 2015
This article was originally published in Start Up
Executive Summary
Start-ups raised $2.41 billion in Q4 2015. Biopharma companies penned 29 alliances; seven acquisitions were signed in the biopharma and diagnostics industries.
You may also be interested in...
The A-List: The Trend-Shaping Series A Financings Of 2015
Our 12th annual analysis reveals both an expansion of historical patterns of Series A financings and the emergence of a new group of heavily committed, relatively short-term investors.
Boston Pharmaceuticals: A New Model To De-Risk Drugs
Christopher Viebacher's new venture Boston Pharmaceuticals was established with enough capital - $600 million - to scour thousands of Phase-I ready programs and build a portfolio of 20 to 25 early-stage drug candidates that it will attempt to de-risk then sell or license to interested partners
Deals In Depth: October 2021
Six $1bn+ alliances were penned in October. Topping the list was a potential $3.6bn deal between Poseida Therapeutics and Takeda to utilize Poseida's genetic engineering platforms for the research and development of up to eight gene therapies. The collaboration will focus on non-viral in vivo gene therapy programs, including Poseida's preclinical hemophilia A program P-FVIII-101. Poseida will lead research activities up to candidate selection, after which Takeda will assume responsibility for further exclusive global development and commercialization.